Summary
A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe illness from RSV first became available.
Source: The Philadelphia Inquirer on MSN.com
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
